GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Asset Turnover

Shanghai Henlius Biotech (HKSE:02696) Asset Turnover : 0.29 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Shanghai Henlius Biotech's Revenue for the six months ended in Dec. 2024 was HK$3,180 Mil. Shanghai Henlius Biotech's Total Assets for the quarter that ended in Dec. 2024 was HK$11,029 Mil. Therefore, Shanghai Henlius Biotech's Asset Turnover for the quarter that ended in Dec. 2024 was 0.29.

Asset Turnover is linked to ROE % through Du Pont Formula. Shanghai Henlius Biotech's annualized ROE % for the quarter that ended in Dec. 2024 was 30.94%. It is also linked to ROA % through Du Pont Formula. Shanghai Henlius Biotech's annualized ROA % for the quarter that ended in Dec. 2024 was 8.41%.


Shanghai Henlius Biotech Asset Turnover Historical Data

The historical data trend for Shanghai Henlius Biotech's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Asset Turnover Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial 0.10 0.25 0.38 0.57 0.55

Shanghai Henlius Biotech Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.27 0.30 0.27 0.29

Competitive Comparison of Shanghai Henlius Biotech's Asset Turnover

For the Biotechnology subindustry, Shanghai Henlius Biotech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Asset Turnover falls into.


;
;

Shanghai Henlius Biotech Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Shanghai Henlius Biotech's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=6111.834/( (10832.317+11314.676)/ 2 )
=6111.834/11073.4965
=0.55

Shanghai Henlius Biotech's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=3179.89/( (10743.646+11314.676)/ 2 )
=3179.89/11029.161
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Shanghai Henlius Biotech  (HKSE:02696) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Shanghai Henlius Biotech's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=927.1/2996.5825
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(927.1 / 6359.78)*(6359.78 / 11029.161)*(11029.161/ 2996.5825)
=Net Margin %*Asset Turnover*Equity Multiplier
=14.58 %*0.5766*3.6806
=ROA %*Equity Multiplier
=8.41 %*3.6806
=30.94 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2024) net income data. The Revenue data used here is two times the semi-annual (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Shanghai Henlius Biotech's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=927.1/11029.161
=(Net Income / Revenue)*(Revenue / Total Assets)
=(927.1 / 6359.78)*(6359.78 / 11029.161)
=Net Margin %*Asset Turnover
=14.58 %*0.5766
=8.41 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2024) net income data. The Revenue data used here is two times the semi-annual (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Shanghai Henlius Biotech Asset Turnover Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech Business Description

Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Qatar Investment Authority 2201 Interest of corporation controlled by you
Ubs Group Ag
Golden Valley Value Select Master Fund 2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Lvc Sg Management Pte. Ltd. 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lin Lijun 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines